Clinical Trial Update: Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial update describing targeted dose finding for canakinumab in acute gout patients who are refractory or contraindicated, with the study completed a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Acute Gout | Phase 2 | Status: COMPLETED | Results posted: 2011-05-16